Preliminary HTA fail for BMS/AZ's Forxiga in Germany
This article was originally published in Scrip
Bristol-Myers Squibb and AstraZeneca are the latest companies to fail Germany's AMNOG health technology appraisal data requirements. They have not supplied enough evidence to show that their Forxiga (dapagliflozin) offers any benefit over competitors already on the market, says IQWiG, the institute that carries out the preliminary benefit assessment.
You may also be interested in...
Public health advocates say that commercial concerns must take a back seat to health interests if COVID-19 technologies are to be made available to those who need them. But industry says that relaxing IP protections is not the solution and that many companies have already invested significant amounts of money in potential new treatments and vaccines.
Recommending new medicines for approval and allowing sponsors of others extra time to answer outstanding questions are among the many tasks on the agenda of the March meeting of European Medicines Agency's key scientific committee, the CHMP. The meeting has been taking place, remotely, this week.
Intellectual property rights are under the microscope as countries prepare to provide affordable and timely access to pandemic technologies.